Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the Company’s holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority. Genmab's share capital will be updated in Nasdaq's system as soon as possible and expectedly on M ...

Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from March 31 to April 4, 2025: Trading PlatformNo. of sharesAverage price (D ...

Media Release COPENHAGEN, Denmark; March 31, 2025 Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic ce ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy.Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for cervical cancer in Japan.The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced or recurrent cervical c ...

Media ReleaseCOPENHAGEN, Denmark; March 27, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in JapanApproval is based on results from the global Phase 3 innovaTV 301 trial, in which TIVDAK demonstrated superior overall survival compared to chemotherapyRising cervical cancer incidence and mortality rates in Japan signify need for new treatment options Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, ...

Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock Unit programCompletion expected no later than July 10, 2025 COPENHAGEN, Denmark; March 25, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be und ...

Core Viewpoint - AbbVie Inc. has filed a lawsuit against Genmab A/S and others, alleging misappropriation of trade secrets related to disaccharides used in antibody-drug conjugates (ADCs) [1][2][3] Group 1: Legal Proceedings - AbbVie is seeking damages and broad injunctive reliefs, claiming that Genmab and others have misappropriated its trade secrets [2] - Genmab categorically refutes the allegations and intends to vigorously defend against AbbVie's claims [2][3] - This lawsuit is part of a series of recent legal actions by AbbVie against competitors for similar allegations [3] Group 2: Product Information - The complaint pertains to Rina-S™, a clinical-stage ADC targeting FRα, currently in Phase 3 development for ovarian cancer and other solid tumors [4] - Rina-S™ utilizes a proprietary antibody and a unique linker to achieve a drug-to-antibody ratio (DAR) of 8 for the payload, exatecan [4] - Genmab aims to broaden the development plans for Rina-S™ based on ongoing clinical trial data, potentially addressing a wider patient population in ovarian cancer [5] Group 3: Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody-based medicines [6][9] - The company has a strong track record in the discovery and commercialization of differentiated antibody therapeutics [6] - Genmab's vision by 2030 is to transform the lives of patients with cancer through advanced antibody medicines [9]

Core Insights - Genmab A/S announced promising results from the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S), showing a confirmed objective response rate (ORR) of 55.6% in heavily pre-treated ovarian cancer patients [2][4][8] - The study highlights the potential of Rina-S as a treatment option for patients with platinum-resistant ovarian cancer (PROC), a group with historically poor prognosis [3][6] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics, with a vision to transform cancer treatment by 2030 [13][14] - The company is headquartered in Copenhagen, Denmark, and has a global presence across North America, Europe, and Asia Pacific [14] Study Details - The RAINFOL-01 trial is an open-label, multicenter Phase 1/2 study evaluating the safety and efficacy of Rina-S in solid tumors expressing folate receptor-alpha (FRα) [7] - The B1 cohort specifically targets advanced ovarian cancer, with patients receiving either 100 mg/m or 120 mg/m doses of Rina-S [4][9] Clinical Results - In the B1 cohort, Rina-S at 120 mg/m resulted in a confirmed ORR of 55.6% and a disease control rate (DCR) of 88.9% [4][8] - The median duration of response (mDOR) was not reached, indicating sustained efficacy [4][8] - Common treatment-emergent adverse events included anemia, nausea, and fatigue, but no new safety signals were observed [5][6] Future Directions - Rina-S 120 mg/m has been selected for further evaluation in ongoing Phase 3 trials (RAINFOL-02) for PROC patients [4][11] - The FDA granted Fast Track designation to Rina-S for treating FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer [11]

Core Viewpoint - Genmab A/S's shares declined following Johnson & Johnson's decision to withdraw from the partnership to develop and commercialize GEN3014, a next-generation CD38 HexaBody aimed at treating multiple myeloma [2]. Group 1: Company Developments - Johnson & Johnson opted out of the deal with Genmab for the development of GEN3014, which is significant for Genmab's pipeline in oncology [2]. - The withdrawal from the partnership is expected to impact Genmab's stock performance negatively, as indicated by the recent decline in share prices [2]. Group 2: Market Context - The decision by Johnson & Johnson reflects broader trends in the biotech industry, where partnerships are crucial for the development and commercialization of new therapies [2].

Company Announcement - Genmab A/S held its Annual General Meeting on March 12, 2025, where the Board of Directors was constituted, appointing Ms. Deirdre P. Connelly as Chair and Ms. Pernille Erenbjerg as Deputy Chair [1] - The Board decided to grant 13,926 restricted stock units to members of the Board and employees, along with 4,214 warrants to employees [1] Restricted Stock Units - Each restricted stock unit is awarded cost-free and provides a conditional right to receive one share of Genmab A/S, with a fair value of DKK 1,372.50 per unit [2] - The restricted stock units will vest three years after the grant date, subject to specific vesting conditions [3] Warrants - Each warrant is awarded cost-free, with an exercise price of DKK 1,372.50, allowing the owner to subscribe for one share [4] - The fair value of each warrant is calculated at DKK 421.30, and they will vest three years after the grant date, expiring at the seventh anniversary of the grant date [5] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform the lives of people with cancer and serious diseases by 2030 [6] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [7]